Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 12/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147188 | 0.91 | MAOA (0.54) | MAOAMAOBKMT2ATSHRPLA2G2A | |
| SCHEMBL4169248 | 0.91 | HASPIN (0.61) | MAOAKMT2ATSHRMAPK1PLA2G2A | |
| SCHEMBL27351040 | 0.86 | MAOA (0.51) | MAOAMAOBKMT2ATSHRMAPK1 | |
| SCHEMBL20135935 | 0.86 | MAOA (0.51) | MAOAMAOBKMT2ATSHRMAPK1 | |
| SCHEMBL20135929 | 0.86 | MAOA (0.51) | MAOAMAOBKMT2APLA2G2AHASPIN | |
| SCHEMBL27350987 | 0.85 | MAOA (0.50) | MAOAMAOBKMT2APLA2G2AHASPIN | |
| SCHEMBL27348493 | 0.83 | MAOA (0.48) | MAOAMAOBKMT2APLA2G2AHASPIN | |
| SCHEMBL24276798 | 0.82 | KMT2A (0.48) | MAOAMAOBKMT2ATSHRMAPK1 | |
| SCHEMBL29445065 | 0.82 | KMT2A (0.48) | MAOAMAOBKMT2ATSHRMAPK1 | |
| SCHEMBL27348494 | 0.82 | MAOA (0.47) | MAOAMAOBKMT2ATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538529-B1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-KB PATHWAYS | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT (DE) | 2022-01-19 | — | — | EP | disclosed |
| EP-3538529-B1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-KB PATHWAYS | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT (DE) | 2022-01-19 | — | — | EP | disclosed |
| US-11028084-B2 | Selective inhibitors of gentotoxic steress-induced IKK/NF-κB pathways | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2021-06-08 | — | — | US | disclosed |
| US-11028084-B2 | Selective inhibitors of gentotoxic steress-induced IKK/NF-κB pathways | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2021-06-08 | — | — | US | disclosed |
| US-20190276452-A1 | SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-09-12 | — | — | US | disclosed |
| US-20190276452-A1 | SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-09-12 | — | — | US | disclosed |
| WO-2018087389-A1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-kB PATHWAYS | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2018-05-17 | — | — | WO | disclosed |
| EP-3321264-A1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-KB PATHWAYS | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2018-05-16 | — | — | EP | disclosed |
| EP-3321264-A1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-KB PATHWAYS | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028084-B2 | Selective inhibitors of gentotoxic steress-induced IKK/NF-κB pathways | IKBKB, NFKBIA, IKBKE | MAOA 4067/4885MAOB 2939/4885KMT2A 2389/4885 |
| US-20190276452-A1 | SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS | IKBKB, NFKBIA, IKBKE | MAOA 4036/4885MAOB 2093/4885KMT2A 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.